Polymer nanoparticles loaded with FeCl-tetraphenylporphyrin for binary catalytic therapy of neoplasms
- Авторлар: Faustova M.1, Nikolskaya E.1, Zhunina O.1, Mollaev M.1, Yabbarov N.1, Lobanov A.2,3, Melnikov M.4, Severin E.1
-
Мекемелер:
- OJSC Russian Research Center for Molecular Diagnostics and Therapy
- N. N. Semenov Institute of Chemical Physics, Russian Academy of Sciences
- G. V. Plekhanov Russian University of Economics
- Department of Chemistry, M. V. Lomonosov Moscow State University, Build. 3
- Шығарылым: Том 67, № 2 (2018)
- Беттер: 359-365
- Бөлім: Full Articles
- URL: https://journals.rcsi.science/1066-5285/article/view/242232
- DOI: https://doi.org/10.1007/s11172-018-2081-z
- ID: 242232
Дәйексөз келтіру
Аннотация
In order to study the possibility of using a metal complex of the porphyrin series, FeIIICl-tetraphenylporphyrin (FeClTPP), and its polymeric form as antitumor agents for binary catalytic therapy, the technology of preparation of polymer particles containing FeClTPP was developed for the first time. The experimental data obtained allow one to conclude that the developed form using a copolymer of lactic and glycolic acids (ratio of monomer units 50: 50), ultrasonic homogenization, D-mannitol (as a cryoprotectant), the active agent to polymer ratio 1: 10, and the organic to aqueous phase ratio 1: 10 and 1: 20, respectively, has the optimal physicochemical parameters. It was found that the free substance of FeClTPP and polymer particles with FeClTPP are active against MCF-7 (human breast adenocarcinoma), HeLa (human cervical carcinoma), and MG-63 (human osteosarcoma) cell lines. The polymer particles containing FeClTFP exhibit the highest cytotoxic effect against MCF-7 lines as compared to the free substance. The results of the study indicate that both the substance of tetraphenylporphyrin and its resulting polymeric form are promising for the treatment of tumor diseases in binary catalytic therapy.
Авторлар туралы
M. Faustova
OJSC Russian Research Center for Molecular Diagnostics and Therapy
Email: e.severin@mail.ru
Ресей, 8 Simferopolsky bulv., Moscow, 117149
E. Nikolskaya
OJSC Russian Research Center for Molecular Diagnostics and Therapy
Email: e.severin@mail.ru
Ресей, 8 Simferopolsky bulv., Moscow, 117149
O. Zhunina
OJSC Russian Research Center for Molecular Diagnostics and Therapy
Email: e.severin@mail.ru
Ресей, 8 Simferopolsky bulv., Moscow, 117149
M. Mollaev
OJSC Russian Research Center for Molecular Diagnostics and Therapy
Email: e.severin@mail.ru
Ресей, 8 Simferopolsky bulv., Moscow, 117149
N. Yabbarov
OJSC Russian Research Center for Molecular Diagnostics and Therapy
Email: e.severin@mail.ru
Ресей, 8 Simferopolsky bulv., Moscow, 117149
A. Lobanov
N. N. Semenov Institute of Chemical Physics, Russian Academy of Sciences; G. V. Plekhanov Russian University of Economics
Email: e.severin@mail.ru
Ресей, 4 ul. Kosygina, Moscow, 119991; 36 Stremyannyi per., Moscow, 117997
M. Melnikov
Department of Chemistry, M. V. Lomonosov Moscow State University, Build. 3
Хат алмасуға жауапты Автор.
Email: melnikov46@mail.ru
Ресей, 1 Leninskiye Gory, Moscow, 119991
E. Severin
OJSC Russian Research Center for Molecular Diagnostics and Therapy
Хат алмасуға жауапты Автор.
Email: e.severin@mail.ru
Ресей, 8 Simferopolsky bulv., Moscow, 117149